HYPE3 Stock Chart & Stats
$20.10
-$0.20(-0.99%)
―
--
Day’s Range― - ―
52-Week Range$19.88 - $27.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
R$14.28B
Enterprise Value$21.32K
Total Cash (Recent Filing)R$2.31B
Total Debt (Recent Filing)R$8.72B
Price to Earnings (P/E)7.6
Beta1.06
Next Earnings
Aug 06, 2026EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.66
Shares Outstanding704,009,030
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)1.20
Price to Sales (P/S)1.96
P/FCF Ratio16.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
R$30.57Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HYPE3 FAQ
What was Hypera S.A.’s price range in the past 12 months?
Hypera S.A. lowest stock price was $19.88 and its highest was $27.51 in the past 12 months.
What is Hypera S.A.’s market cap?
Hypera S.A.’s market cap is R$14.28B.
When is Hypera S.A.’s upcoming earnings report date?
Hypera S.A.’s upcoming earnings report date is Aug 06, 2026 which is in 12 days.
How were Hypera S.A.’s earnings last quarter?
Hypera S.A. released its earnings results on Apr 28, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.457 by $0.033.
Is Hypera S.A. overvalued?
According to Wall Street analysts Hypera S.A.’s price is currently Undervalued.
Does Hypera S.A. pay dividends?
Hypera S.A. does not currently pay dividends.
What is Hypera S.A.’s EPS estimate?
Hypera S.A.’s EPS estimate is 0.66.
How many shares outstanding does Hypera S.A. have?
Hypera S.A. has 704,009,030 shares outstanding.
What happened to Hypera S.A.’s price movement after its last earnings report?
Hypera S.A. reported an EPS of $0.49 in its last earnings report, beating expectations of $0.457. Following the earnings report the stock price went up 3.27%.
Which hedge fund is a major shareholder of Hypera S.A.?
Currently, no hedge funds are holding shares in BR:HYPE3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hypera S.A.
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
HYPE3 Stock 12 Month Forecast
Average Price Target
$30.57
Allos S.A.
―
Blau Farmaceutica SA
―
Galapagos NV Unsponsored Brazilian Depositary Receipt Repr 0.05 ADR
―
Ultragenyx Pharmaceutical Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh
―
DENTSPLY SIRONA, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
―